These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 30015691

  • 1. Treatment of hormone-naïve metastatic prostate cancer.
    Hamilou Z, Saad F, Fizazi K.
    Curr Opin Support Palliat Care; 2018 Sep; 12(3):334-338. PubMed ID: 30015691
    [Abstract] [Full Text] [Related]

  • 2. Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!
    Messina C, Messina M, Boccardo F.
    Eur Urol; 2018 Jan; 73(1):147-148. PubMed ID: 28801126
    [No Abstract] [Full Text] [Related]

  • 3. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M, Sweeney C, Antonarakis ES, Armstrong AJ.
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [Abstract] [Full Text] [Related]

  • 4. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
    Lavaud P, Gravis G, Foulon S, Joly F, Oudard S, Priou F, Latorzeff I, Mourey L, Soulié M, Delva R, Krakowski I, Laguerre B, Théodore C, Ferrero JM, Beuzeboc P, Habibian M, Rolland F, Deplanque G, Pouessel D, Zanetta S, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Tubiana-Mathieu N, Machiels JP, Kouri CE, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Culine S, Boher JM, Tergemina-Clain G, Legoupil C, Fizazi K.
    Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
    [Abstract] [Full Text] [Related]

  • 5. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [Abstract] [Full Text] [Related]

  • 6. The evolving options in metastatic castration-sensitive prostate cancer.
    Hamilou Z.
    Curr Opin Support Palliat Care; 2020 Sep; 14(3):270-275. PubMed ID: 32701855
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.
    Eur Urol; 2018 Jun; 73(6):834-844. PubMed ID: 29037513
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Metastatic prostate cancer : Update: position paper for the use of chemotherapy].
    Ohlmann CH, Goebell PJ, Grimm MO, Klier J, König F, Machtens S, Schostak M, Schrader AJ, Albers P.
    Urologe A; 2017 Dec; 56(12):1597-1602. PubMed ID: 28695241
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
    Kretschmer A, Todenhöfer T.
    Eur Urol Focus; 2019 Mar; 5(2):114-116. PubMed ID: 30482584
    [Abstract] [Full Text] [Related]

  • 14. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 15. Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.
    Sun G, Chen X, Gong U, Chen Y, Li G, Wei F, Jiang A, Niu Y, Shang Z.
    Future Oncol; 2019 Apr; 15(10):1167-1179. PubMed ID: 30741558
    [Abstract] [Full Text] [Related]

  • 16. What kind of patients with castration-naïve prostate cancer can benefit from upfront docetaxel and abiraterone: A systematic review and a network meta-analysis.
    Sun G, Zhang X, Chen J, Liao B, Liu Z, Zhao J, Gao AC, Yang Y, Shu K, Liu J, Zhao P, Shen P, Zeng H.
    Urol Oncol; 2018 Dec; 36(12):505-517. PubMed ID: 30316578
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHAARTED and GETUG-AFU15 Studies.
    Gravis G, Boher JM, Chen YH, Liu G, Fizazi K, Carducci MA, Oudard S, Joly F, Jarrard DM, Soulie M, Eisenberger MJ, Habibian M, Dreicer R, Garcia JA, Hussain MHM, Kohli M, Vogelzang NJ, Picus J, DiPaola R, Sweeney C.
    Eur Urol; 2018 Jun; 73(6):847-855. PubMed ID: 29475737
    [Abstract] [Full Text] [Related]

  • 20. Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, Celano P, Bangs R, Milowsky MI.
    J Clin Oncol; 2018 May 20; 36(15):1521-1539. PubMed ID: 29608397
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.